Amgen Inc. reported second quarter 2026 financial results on August 4, 2026. Total revenues increased 10% to $10.1 billion, driven by a 9% rise in product sales. GAAP earnings per share rose 65% to $4.37, while non-GAAP EPS increased 4% to $6.29. The company generated $3.5 billion in free cash flow and declared a quarterly dividend of $2.52 per share, paid on June 5, 2026, representing a 6% increase from the prior year. Full-year 2026 guidance projects total revenues between $38.2 billion and $39.4 billion and non-GAAP EPS between $22.30 and $23.50. Amgen Inc. operates in the biotechnology industry, discovering, developing, manufacturing, and delivering innovative medicines to treat cancer, heart disease, inflammatory conditions, rare diseases, and obesity.

Amgen Inc. disclosed a material cybersecurity incident in July 2026 involving unauthorized access to data stored in third-party cloud environments. The company confirmed that proprietary data, patient protected health information (PHI), and other sensitive information were exfiltrated. Amgen activated its response plan, implemented containment measures, and engaged independent forensic experts. While the investigation remains ongoing, the company stated there is no impact on products, manufacturing operations, or financial reporting systems. The incident was deemed material due to the volume of files and sensitivity of the data, though it is not expected to materially affect financial condition or results of operations. Amgen Inc. operates in the biotechnology industry, developing and commercializing human therapeutics.

Amgen announced that CFO Peter H. Griffith will retire on August 31, 2026, and will be succeeded by Thomas Dittrich effective September 1, 2026. The transition involves a significant compensation package for Dittrich, including a CHF 1,070,000 base salary and one-time incentives such as a CHF 4,700,000 RSU grant and a CHF 4,000,000 cash bonus to offset foregone equity. This leadership succession is a key development for investors monitoring the company's financial management and strategic continuity.

Amgen Inc. has released its unaudited financial results for the first quarter of 2026. The filing outlines the company's non-GAAP reconciliation methodology, which excludes acquisition-related and restructuring costs to help investors better evaluate core operating performance.

Amgen Inc. announced that David M. Reese will retire as Executive Vice President and Chief Technology Officer on June 30, 2026. His responsibilities will be redistributed among the heads of R&D, Global Markets and Policy, and the CFO starting June 1, 2026, to better integrate the company's science, technology, and data functions. This leadership transition signals a structural reorganization of technology and data oversight across Amgen's senior management.